Chlitina Holding Ltd. AI Stock Analysis
Chlitina Holding Ltd. (4137) AI Stock Analysis
Chlitina Holding Ltd.
(TWSE:4137)
Chlitina scores moderately. The core driver is a financially sound but fading franchise: outstanding gross margins, solid equity funding and a strong 2025 recovery in profit and free cash flow are offset by a multi-year revenue decline, operating margins halving to 19%, falling returns on equity and a 45% increase in debt. Technicals are the main drag, with the share price below all major moving averages and negative MACD momentum. Partially offsetting this is an attractive valuation — an 11.2x P/E and a 13.2% dividend yield — which provides meaningful support if the company can stabilise its top line and margins. No earnings call or corporate event data was available, so the score rests on fundamentals, technicals and valuation.
Chlitina Holding Ltd. (4137) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 6.40B
- Dividend Yield
- 12.80%
- Average Volume (3M)
- 202.90K
- Price to Earnings (P/E)
- 10.3
- Beta (1Y)
- 0.32
- Revenue Growth
- 7.53%
- EPS Growth
- 25.66%
- Country
- TW
- Employees
- 123,543
- Sector
- General
- Sector Strength
- 55
- Industry
- Household & Personal Products
Chlitina Holding Ltd. Business Overview & Revenue Model
Company Description
Chlitina Holding Limited, an investment holding company, engages in the research, development, manufacture, and sale of beauty and skin care products in Taiwan and internationally. The company offers skin care products for basic maintenance, serum, a...
Chlitina Holding Ltd. Financial Statement Overview
Summary
Chlitina combines elite gross margins above 82% with a majority equity-funded balance sheet and consistently positive free cash flow, which rebounded strongly to NT$618m in 2025 alongside a 24% jump in net income and a 46% rise in operating cash flow. However, the top line has fallen roughly 26% from its 2021 peak, operating margin has nearly halved to 19%, return on equity has slid to 11% from over 20%, and total debt rose about 45% in 2025, pushing leverage toward the high end of its historical range. Cash flow is also volatile year to year, leaving a financially stable but structurally weakening earnings profile.
Income Statement
56NeutralBalance Sheet
64PositiveCash Flow
66Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.03B | 3.88B | 4.07B | 4.53B | 4.07B | 5.27B |
| Gross Profit | 3.22B | 3.18B | 3.37B | 3.79B | 3.36B | 4.38B |
| EBITDA | 923.57M | 1.03B | 1.18B | 1.93B | 1.57B | 2.10B |
| Net Income | 556.86M | 588.00M | 472.68M | 1.03B | 689.86M | 1.36B |
Balance Sheet | ||||||
| Total Assets | 10.01B | 9.52B | 8.89B | 8.91B | 8.60B | 10.04B |
| Cash, Cash Equivalents and Short-Term Investments | 6.23B | 5.90B | 5.50B | 5.79B | 5.64B | 7.02B |
| Total Debt | 2.97B | 2.97B | 2.05B | 2.34B | 2.59B | 3.01B |
| Total Liabilities | 5.07B | 4.25B | 3.35B | 3.76B | 3.94B | 5.04B |
| Stockholders Equity | 4.94B | 5.28B | 5.54B | 5.15B | 4.65B | 4.99B |
Cash Flow | ||||||
| Free Cash Flow | 725.29M | 618.35M | 84.61M | 979.42M | 154.08M | 1.70B |
| Operating Cash Flow | 815.21M | 838.80M | 574.54M | 1.23B | 277.55M | 1.80B |
| Investing Cash Flow | -840.86M | -221.49M | -1.28B | -1.37B | 962.71M | -578.42M |
| Financing Cash Flow | -110.39M | -164.00M | -796.41M | -750.68M | -1.60B | -440.23M |
Chlitina Holding Ltd. Peers Comparison
Overall Rating
TW:173767Neutral
TW:173464Neutral- TW:413760Neutral
TW:179945Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:1737 | 67Neutral | TWD 5.98B | 15.74 | ― | 4.71% | -2.24% | 12.99% |
| TW:1734 | 64Neutral | TWD 6.07B | 17.33 | ― | 3.13% | 2.44% | -3.96% |
| TW:4137 | 60Neutral | TWD 6.48B | 10.33 | ― | 12.80% | 7.53% | 25.66% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:1799 | 45Neutral | TWD 6.24B | -264.14 | ― | ― | 59.53% | 83.16% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4137 | Chlitina Holding Ltd. | 78.10 | -12.85 | -14.13% | |
| TW:1734 | Sinphar Pharmaceutical Co. Ltd. | 30.15 | 1.76 | 6.19% | |
| TW:1737 | Taiyen Biotech Co. Ltd. | 29.75 | -0.73 | -2.39% | |
| TW:1799 | Easywell Biomedicals, Inc. | 24.55 | -9.10 | -27.04% | |
| TW:7876 | Obigen Pharma, Inc. | 66.20 | 29.51 | 80.45% | |
| TW:7878 | Pharmasaga Co., Ltd. | 140.00 | -135.62 | -49.20% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026